Advanced glycation end product is implicated in amyloid‐related kidney complications

References

• Andrade C. A peculiar form of peripheral polyneuropathy: familial atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952;75:408–27.
   PubMed Web of Science ®Google Scholar
• Saraiva MJ, Costa PP, Birken S, Goodman DS. Presence of an abnormal transthyretin (prealbumin) in Portuguese patients with familial amyloidotic polyneuropathy. Trans Assoc Am Physicians 1983;96:261–70.
   PubMedGoogle Scholar
• Peterson SA, Klabunde T, Lashuel HA, Purkey H, Sacchettini JC, Kelly JW. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc Natl Acad Sci 1998;95:12956–60.
   PubMed Web of Science ®Google Scholar
• Suhr O, Ericzon BG, Friman S. Long-term follow-up of survival of liver transplant recipients with familial amyloid polyneuropathy (Portuguese type). Liver Transpl 2002;8:787–94.
   Google Scholar
• Ikeda S, Yanagisawa N, Hongo M, Ito N. Vagus nerve and celiac ganglion lesions in generalized amyloidosis. A correlative study of familial amyloid polyneuropathy and AL-amyloidosis. J Neurol Sci 1987;79:129–39.
   Google Scholar
• Olofsson B-0, Suhr O, Niklasson U, Wiklund U, Bjerle P, Beckman A. Assessment of autonomic nerve function in familial amyloidotic polyneuropathy: a clinical study based on spectral analysis of heart rate variability. Amyloid Int J Exp Clin Invest 1994;1: 138–42.
   Google Scholar
• Lobato L, Beirao I, Guimaraes SM, Droz D, Guimaraes S, Grunfeld J, et al. Familial amyloid polyneuropathy type I (Portuguese): distribution and characterization of renal amyloid deposits. Am J Kidney Dis 1998;31:940–6.
   PubMed Web of Science ®Google Scholar
• Ruderman N, Wiliamson J, Brownlee M. Glucose and diabetic vascular disease. FASEB J 1992;6:2905–14.
   Google Scholar
• Schmidt AM, Yan SD, Stern DM. The dark side of glucose. Nature Med 1995;1:1002–4.
   PubMed Web of Science ®Google Scholar
• Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315–21.
   Google Scholar
• Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001;44:129–46.
   PubMed Web of Science ®Google Scholar
• Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end product, N(-(Carboxymethyplysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996;271:9982–6.
   PubMed Web of Science ®Google Scholar
• Thornalley PJ. Cell activation by glycated proteins, AGE receptors receptor recognition factors and functional classification of AGE. Cell Mol Biol 1998;44:1013–23.
   PubMed Web of Science ®Google Scholar
• Lander HM, Tauras JM, Ogiste JS, Hon O, Moss RA, Schmidt AM. Activation for the receptor for AGE triggers p21 ras dependent mitogen activated protein kinase pathway regulated by oxidative stress. J Biol Chem 1997;272:17810–4.
   PubMed Web of Science ®Google Scholar
• Monnier VM, Glomb M, Elgawish A, Sell DR. The mechanism of collagen cross-linking in diabetes: a puzzle nearing resolution. Diabetes 1996;45 Suppl 3:S67–72.
   Google Scholar
• Makino H, Shikata K, Hironaka K, Kushiro M, Yamasaki Y, Sugimoto H, et al. Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. Kidney Int 1995;48:517–26.
   PubMed Web of Science ®Google Scholar
• Yamada K, Nakano H, Nakayama M, Nozaki O, Miura Y, Suzuki S, et al. Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure. Clin Nephrol 1994;42:354–61.
   PubMed Web of Science ®Google Scholar
• Kume S, Takeya M, Mori T, Araki N, Suzuki H, Horiuchi S, et al. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol 1995;147:654–67.
   PubMed Web of Science ®Google Scholar
• Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci 1994;91:4766–70.
   PubMed Web of Science ®Google Scholar
• Kimura T, Takamatsu J, Araki N, Goto M, Kondo A, Miyakawa T, et al. Are advanced glycation end-products associated with amyloidosis in Alzheimer's disease? Neuroreport 1995;6:866–8.
   PubMedGoogle Scholar
• Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci 1994;91:5710–4.
   PubMed Web of Science ®Google Scholar
• Sousa MM, Yan SD, Stern D, Saraiva MJ. Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NEkB) activation. Lab Invest 2000;80:1101–10.
   PubMed Web of Science ®Google Scholar
• Matsunaga N, Anan I, Forsgren S, Nagai R, Rosenberg P, Horiuchi S, Ando Y, Suhr OB. Advanced glycation end products (AGE) and the receptor for AGE are present in gastrointestinal tract of familial amyloidotic polyneuropathy patients but do not induce NF-kappaB activation. Acta Neuropathol 2002;104:441–7.
   PubMedGoogle Scholar
• Makita Z, Vlassara H, Cerami A, Bucala R Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992;267:5133–8.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y. Immunological evidence that non-carboxymethyl lysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Biol 2000;6:114–25.
   Google Scholar
• Miyoshi H. Diabetic nephropathy and low molecular weight advanced glycation end-product in urine. Hokkaido Igaku Zasshi 2000;75:169–78.
   PubMedGoogle Scholar
• Anan I, El-Salhy M, Ando Y, Terazaki H, Sakashita N, Suhr OB. Comparison of amyloid deposits and infiltration of enteric nervous system in upper with those in the lower gastrointestinal tract in patients with familial amyloidotic polyneuropathy. Acta Neuropathol 2001;102:227–32.
   PubMed Web of Science ®Google Scholar
• Miyata T, Kurokawa K, van Ypersele de Strihou C. Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney hit Suppl 2000;76:5120–5.
   Google Scholar
• Gugliucci A, Bendayan M. Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 1996;39:149–60.
   PubMed Web of Science ®Google Scholar
• Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000;11:1656–66.
   PubMed Web of Science ®Google Scholar
• Shimoike T, Inoguchi T, Umeda F, Nawata H, Kawano K, Ochi H. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism 2000;49:1030–5.
   PubMedGoogle Scholar
• Sebokova K, Podracka L, Heidland A, Schinzel R. Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation: are they inter-related? Clin Nephrol 2001;56: 521–6.
   Google Scholar
• Bonnefont-Rousselot D. Glucose and reactive oxygen species. Curr Opin Clin Nutr Metab Care 2002;5:561–8.
   PubMed Web of Science ®Google Scholar
• Ando Y, Nyhlin N, Suhr OB, Holmgren G, Uchida K, El Sahly M, et al. Oxidative stress is found in amyloid deposits in systemic amyloidosis. Biochem Biophys Res Commun 1997;232:497–502.
   PubMed Web of Science ®Google Scholar
• Nyhlin N, Anan I, El Salhy M, Ando Y, Suhr OB. Reduction of free radical activity in amyloid deposits following liver transplantation for familial amyloidotic polyneuropathy. J Intern Med 2002;251:136–41.
   Google Scholar
• Nowak G, Suhr OB, Wikström L, Wilczik H, Ericzon B-G. Long-term impact of liver transplantation on familial amyloidotic polyneuropathy patients' kidney function [abstract]. Presented at The 5th International Symposium on Familial Amyloidotic Polyneuropathy and other Transthyretin-Related Disorders and The 4th International Workshop on Liver Transplantation in Familial Amyloid Polyneuropathy. Matsumoto, Japan; 2002.
   Google Scholar
• Makita Z, Radoff S, Rayfield E, Yang Z, Skolnik E, Delaney V, et al. Advanced glycosylation end products in patients with diabetic neuropathy. N Engl J Med 1991;325:836–42.
   PubMed Web of Science ®Google Scholar
• Wagner Z, Wittmann I, Mazak I, Schinzel R, Heidland A, Kientsch-Engel R, et al. N(epsilon)-(carboxyrnethyl)lysine levels in patients with type 2 diabetes: role of renal function. Am J Kidney 2001;38: 785–91.
   Google Scholar
• Izuhara Y, Miyata T, Ueda Y, Suzuki D, Koichi A, Inagi R, et al. A sensitive and specific ELISA for plasma pentosidine. Nephrol Dial Transplant 1999;14:576–80.
   PubMedGoogle Scholar